BOCA RATON, Fla., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc., (NASDAQ: ENTO), (“Entero Therapeutics” or the “Company”), a clinical-stage biopharmaceutical company specializing...
BOCA RATON, Fla., Aug. 23, 2024 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc., (NASDAQ: ENTO), (“Entero Therapeutics” or the “Company”), a clinical-stage biopharmaceutical company specializing...
BOCA RATON, Fla., July 31, 2024 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc., (NASDAQ: ENTO), (“Entero Therapeutics” or the “Company”), a clinical-stage biopharmaceutical company specializing...
New VCIEL scale provides a more sensitive and quantitative metric of small intestinal health for monitoring Celiac Disease severity and treatment efficacy Special editorial highlights the...
BOCA RATON, Fla., May 22, 2024 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc. (formerly First Wave BioPharma, Inc.) (Nasdaq: ENTO) (“Entero” or the “Company”), a late clinical-stage...
BOCA RATON, Fla., May 20, 2024 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc., (NASDAQ: ENTO), (“Entero Therapeutics” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.0392 | -5.99388379205 | 0.654 | 0.716199 | 0.6 | 31039 | 0.66925001 | CS |
4 | 0.1369 | 28.6461602846 | 0.4779 | 0.8655 | 0.447 | 248586 | 0.64895279 | CS |
12 | 0.3198 | 108.406779661 | 0.295 | 0.8655 | 0.2501 | 417007 | 0.54455823 | CS |
26 | -2.3452 | -79.2297297297 | 2.96 | 3.16 | 0.185 | 472657 | 0.4721061 | CS |
52 | -2.3452 | -79.2297297297 | 2.96 | 3.16 | 0.185 | 472657 | 0.4721061 | CS |
156 | -2.3452 | -79.2297297297 | 2.96 | 3.16 | 0.185 | 472657 | 0.4721061 | CS |
260 | -2.3452 | -79.2297297297 | 2.96 | 3.16 | 0.185 | 472657 | 0.4721061 | CS |
Aucune Discussion Trouvée |
Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales